Pharmacological approaches to reducing craving in patients with alcohol use disorders.
about
The Classification of Substance Use Disorders: Historical, Contextual, and Conceptual ConsiderationsMethamphetamine and the hypothalamic-pituitary-adrenal axisAnxiety, Anxiety Sensitivity, and Perceived Stress as Predictors of Recent Drinking, Alcohol Craving, and Social Stress Response in Heavy Drinkers.Pharmacotherapy for alcoholic patients with alcoholic liver diseaseGRIK1 genotype and daily expectations of alcohol's positive effects moderate the reduction of heavy drinking by topiramate.Effects of idazoxan on alcohol pharmacokinetics and intoxication: a preliminary human laboratory study.Early Life Stress, Nicotinic Acetylcholine Receptors and Alcohol Use Disorders.Preclinical evidence implicating corticotropin-releasing factor signaling in ethanol consumption and neuroadaptation.The cortisol level and its relationship with depression, stress and anxiety indices in chronic methamphetamine-dependent patients and normal individuals undergoing inguinal hernia surgery.The Mini Alcohol Craving Experience Questionnaire: Development and Clinical Application.Treatment options for alcoholic and non-alcoholic fatty liver disease: A review.Comparing and Combining Topiramate and Aripiprazole on Alcohol-Related Outcomes in a Human Laboratory Study.A Phase I randomized clinical trial testing the safety, tolerability and preliminary pharmacokinetics of the mGluR5 negative allosteric modulator GET 73 following single and repeated doses in healthy volunteers.Chronic intermittent ethanol exposure selectively alters the expression of Gα subunit isoforms and RGS subtypes in rat prefrontal cortex.Noradrenergic targets for the treatment of alcohol use disorder.Relationship between tonic and phasic craving for alcohol.
P2860
Q26739919-8BCE1F9F-43E2-4E4E-AF62-721FCC9CC5A3Q30409436-51088EF0-79C8-4394-8C26-A962A05F94DFQ33554277-983BFEEE-51B0-4389-AA0D-3D7DE832EB9BQ34223054-FF0DCA4B-67ED-475B-839A-A4759E77E6F9Q34609200-04EB19FE-DC39-4B97-9F45-635E5B35B1ABQ35256306-3F21E083-AFDC-4715-9919-F5CF33E874AAQ36105732-0357EE55-ADD1-4E08-8D18-89305CB3BBF8Q36852840-359DC22A-9715-4B4F-9C0A-65AF31E3A1F9Q37216671-AD92F379-6628-425F-B51C-7F4A4C7D8FA4Q39064361-3728DDCE-7E0B-4917-8197-2A1C0B98EE61Q42695159-081C9955-24CD-4823-AD48-E4DABE6DA5E5Q47569232-BE84B579-C6B2-43A2-B54F-491F2F3F8572Q47753586-41E56300-933C-45F8-BBD5-CA7DD2BE1CC1Q48183212-4722228B-CBB7-4B63-BE11-4BD4350C53F9Q49825421-2B05CE0A-0A84-401E-82D0-FFBE34EA9434Q55003207-1F1168B7-56F4-4306-A22B-55FED350A5EB
P2860
Pharmacological approaches to reducing craving in patients with alcohol use disorders.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacological approaches to reducing craving in patients with alcohol use disorders.
@en
Pharmacological approaches to reducing craving in patients with alcohol use disorders.
@nl
type
label
Pharmacological approaches to reducing craving in patients with alcohol use disorders.
@en
Pharmacological approaches to reducing craving in patients with alcohol use disorders.
@nl
prefLabel
Pharmacological approaches to reducing craving in patients with alcohol use disorders.
@en
Pharmacological approaches to reducing craving in patients with alcohol use disorders.
@nl
P2093
P2860
P1433
P1476
Pharmacological approaches to reducing craving in patients with alcohol use disorders.
@en
P2093
Carolina L Haass-Koffler
George A Kenna
Lorenzo Leggio
P2860
P2888
P304
P356
10.1007/S40263-014-0149-3
P577
2014-04-01T00:00:00Z